8-K: Predictive Oncology Enters Into At-The-Market Offering Agreement with H.C. Wainwright

Predictive Oncology Inc. has entered into an agreement with H.C. Wainwright & Co., LLC to sell up to $3.696 million of its common stock through an at-the-market offering program.

Summary

• Predictive Oncology Inc. has entered into an ATM Sales Agreement with H.C. Wainwright & Co., LLC to sell shares of its common stock.
• The company plans to offer up to $3,696,000 in shares of common stock.
• H.C. Wainwright will act as the sales agent for the offering.
• The sales will be conducted through an at-the-market offering program.
• The company will set parameters for the sale of shares, including the number of shares, time period, and minimum price.
• H.C. Wainwright will receive a commission of 3.0% of the gross sales price of all shares sold.
• The company is not obligated to sell any shares under the agreement and can suspend sales at any time.
• The agreement is subject to the effectiveness of a registration statement on Form S-3 filed with the SEC on May 3, 2024.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. It details a standard capital raising activity, which is neither particularly good nor bad. The company is raising capital, which is necessary for operations, but it also dilutes existing shareholders.

Positives

• The agreement provides Predictive Oncology with a flexible way to raise capital.
• The at-the-market offering allows the company to sell shares gradually over time.
• The company retains control over the timing and pricing of the share sales.
• The company has the option to suspend or terminate the sales agreement if market conditions are unfavorable.

Negatives

• The company will incur a 3.0% commission on all shares sold through H.C. Wainwright.
• The company has no guarantee that all shares will be sold.
• The offering is subject to the effectiveness of a registration statement, which may not be approved.
• The sale of shares could dilute existing shareholders' ownership.

Risks

• The registration statement may not become effective, preventing the sale of shares.
• The company may not be able to sell all the shares it intends to offer.
• The market price of the company's stock could decline during the offering period.
• The offering could dilute the ownership of existing shareholders.
• The company's financial condition could be adversely affected if the offering is not successful.

Future Outlook

The company intends to use the proceeds from the offering as described in the prospectus, but no specific details are provided in this document.

Management Comments

• The company makes no assurances as to whether the Registration Statement will become effective or, if it does become effective, as to the continued effectiveness of the Registration Statement.

Industry Context

At-the-market offerings are a common method for publicly traded companies, particularly in the biotech and pharmaceutical sectors, to raise capital. This allows companies to take advantage of market conditions and raise funds gradually without the need for a large, single offering.

Comparison to Industry Standards

• The 3.0% commission is within the typical range for at-the-market offerings.
• Many small-cap biotech companies use ATM offerings to fund ongoing research and development.
• The offering size of $3.696 million is relatively small, which is common for companies with lower market capitalizations.
• Comparable companies that have used ATM offerings include XOMA Corporation and Agenus Inc.

Stakeholder Impact

• Shareholders may experience dilution of their ownership.
• The company will have additional capital to fund its operations.
• The company's financial stability may improve with the additional funding.

Next Steps

• The company needs to ensure the registration statement becomes effective.
• The company will need to monitor market conditions to determine the optimal timing for share sales.
• The company will need to file a prospectus supplement with the SEC detailing the sales.

Key Dates

Keywords

at-the-market offering, ATM, common stock, capital raise, H.C. Wainwright, Predictive Oncology, sales agreement, equity offering, securities, registration statement